Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer “Evolves” From Rx To Health Care Company: Fla. Medicaid Is Blueprint

Executive Summary

Pfizer plans to follow the blueprint set by its disease management agreement in Florida to forge "creative" agreements with other public and private payors, CFO David Shedlarz told the J.P. Morgan health care conference in San Francisco Jan. 14

You may also be interested in...



“Prior Authorization Assistance” May Be New Tool Under Medicare Rx

Drug manufacturers may want to consider establishing prior authorization assistance programs to prepare for life under Medicare formularies, Parexel Health Policy & Payer Relations Senior Project Manager Tom Snyder said

“Prior Authorization Assistance” May Be New Tool Under Medicare Rx

Drug manufacturers may want to consider establishing prior authorization assistance programs to prepare for life under Medicare formularies, Parexel Health Policy & Payer Relations Senior Project Manager Tom Snyder said

Device Firms Eye Rx Markets; Medtronic Moves Toward “Organ Restoration”

Medtronic's long-term strategy is likely to include a much more prominent role in biotechnology, Senior VP-Medicine & Technology Stephen Oesterle told the recent Wharton Health Care Business Conference in Philadelphia

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel